Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25


Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Melero JA, Mas V, McLellan JS.

Vaccine. 2017 Jan 11;35(3):461-468. doi: 10.1016/j.vaccine.2016.09.045. Epub 2016 Sep 28.


Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Russell CJ, Hurwitz JL.

Expert Rev Vaccines. 2016;15(2):189-200. doi: 10.1586/14760584.2016.1114418. Epub 2015 Dec 9. Review.


Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.

Villenave R, Broadbent L, Douglas I, Lyons JD, Coyle PV, Teng MN, Tripp RA, Heaney LG, Shields MD, Power UF.

J Virol. 2015 Dec;89(24):12309-18. doi: 10.1128/JVI.02119-15. Epub 2015 Sep 30.


A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.

Lambert SL, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B, Sweetwood R, Lei YM, Woo JC, Tang RS.

PLoS One. 2015 Mar 20;10(3):e0119509. doi: 10.1371/journal.pone.0119509. eCollection 2015.


Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf).

Cheon IS, Shim BS, Park SM, Choi Y, Jang JE, Jung DI, Kim JO, Chang J, Yun CH, Song MK.

PLoS One. 2014 Apr 15;9(4):e94269. doi: 10.1371/journal.pone.0094269. eCollection 2014.


A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

Phan SI, Chen Z, Xu P, Li Z, Gao X, Foster SL, Teng MN, Tripp RA, Sakamoto K, He B.

Vaccine. 2014 May 23;32(25):3050-7. doi: 10.1016/j.vaccine.2014.03.049. Epub 2014 Apr 8.


Structure and function of respiratory syncytial virus surface glycoproteins.

McLellan JS, Ray WC, Peeples ME.

Curr Top Microbiol Immunol. 2013;372:83-104. doi: 10.1007/978-3-642-38919-1_4. Review.


Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice.

Noh Y, Shim BS, Cheon IS, Rho S, Kim HJ, Choi Y, Kang CY, Chang J, Song MK, Kim JO.

Viral Immunol. 2013 Aug;26(4):268-76. doi: 10.1089/vim.2012.0087. Epub 2013 Jul 19.


Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.

Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA.

Viral Immunol. 2012 Jun;25(3):193-203. doi: 10.1089/vim.2011.0094. Epub 2012 May 2.


The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents.

Nguyen TN, Power UF, Robert A, Haeuw JF, Helffer K, Perez A, Asin MA, Corvaia N, Libon C.

PLoS One. 2012;7(3):e34331. doi: 10.1371/journal.pone.0034331. Epub 2012 Mar 29.


Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant.

Kim S, Joo DH, Lee JB, Shim BS, Cheon IS, Jang JE, Song HH, Kim KH, Song MK, Chang J.

PLoS One. 2012;7(2):e32226. doi: 10.1371/journal.pone.0032226. Epub 2012 Feb 27.


Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Zeng R, Zhang H, Hai Y, Cui Y, Wei L, Li N, Liu J, Li C, Liu Y.

J Virol. 2012 Apr;86(8):4505-17. doi: 10.1128/JVI.07091-11. Epub 2012 Feb 1.


Respiratory syncytial virus vaccine development.

Hurwitz JL.

Expert Rev Vaccines. 2011 Oct;10(10):1415-33. doi: 10.1586/erv.11.120. Review.


Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells.

Villenave R, O'Donoghue D, Thavagnanam S, Touzelet O, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF.

Virol J. 2011 Jan 27;8:43. doi: 10.1186/1743-422X-8-43.


Respiratory syncytial virus vaccine development.

Murata Y.

Clin Lab Med. 2009 Dec;29(4):725-39. doi: 10.1016/j.cll.2009.07.004. Review.


Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA.

J Virol. 2010 Jan;84(2):1148-57. doi: 10.1128/JVI.01755-09. Epub 2009 Oct 28.


Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22. Epub 2007 Oct 10.


Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase.

Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA.

J Virol. 2007 Apr;81(7):3428-36. Epub 2007 Jan 24.

Supplemental Content

Support Center